The architecture is reasonable, but two things need adjusting before it's clinically actionable.

**1. The right outcome and the right baseline.**

The bulk IFN-γ signature is the clinical-grade baseline you must beat — anything below that performance is not adoptable.

[CLAIM type=published-evidence coverage=well-covered source="Ayers et al 2017, J Clin Invest 127:2930"]The 18-gene IFN-γ-response signature is the most-validated bulk-RNA-seq checkpoint-response biomarker across solid tumors and is computable from FFPE-derived RNA at clinical-lab scale.[/CLAIM]

[CLAIM type=observation coverage=sparse source=""]On osteosarcoma specifically, my training does not contain a definitive numerical AUROC for the IFN-γ signature applied to checkpoint response — I'd hedge that it is plausibly 0.60–0.68 based on transferred pan-cancer performance, but this needs cohort-specific verification.[/CLAIM]

**2. Patient stratification by TFE3 status.**

[CLAIM type=published-evidence coverage=well-covered source="Argani et al 2020, Genes Chromosomes Cancer 59:367 — MiT family translocation tumors"]TFE3-rearranged osteosarcoma is a rare molecular subset; MiT-family transcription factors are documented to modulate lysosomal and immune-related gene programs, which could affect TME composition relative to TFE3-wild-type OS.[/CLAIM]

[NOVEL_SYNTHESIS rationale="if TFE3 fusion modifies macrophage polarization or IFN-γ-response programs, the model must be trained or evaluated stratified by fusion status — otherwise the TFE3 subset's signal is averaged into the larger TFE3-wild-type pool and may be missed"]Training the model on a pan-OS cohort but reporting performance separately on TFE3-fusion patients (and ideally training a TFE3-specific head) would be the honest framing — pooled training, stratified evaluation.[/NOVEL_SYNTHESIS]

**3. Clinically meaningful evaluation.**

[CLAIM type=established-guideline coverage=well-covered source="TRIPOD 2015 reporting guideline"]Calibration (calibration-in-the-large, calibration slope) is required alongside discrimination for any prediction model intended to inform treatment decisions.[/CLAIM]

[CLAIM type=observation coverage=well-covered source=""]Decision-curve analysis at the clinically meaningful threshold (the cost of giving immunotherapy to a non-responder vs withholding it from a responder) is more informative than raw AUROC for whether the model would change practice.[/CLAIM]

**4. The falsifiable prediction.**

The hypothesis should commit to: GNN-with-CD204+M2-typed-edges achieves AUROC ≥ 0.75 on the held-out cohort for checkpoint non-response (RECIST PD at first restaging or no PFS benefit at 6 months), improves over the bulk IFN-γ signature baseline by ≥ 0.07 AUROC with 95% CI lower bound > IFN-γ baseline, with calibration intercept |α| < 0.05 and slope in [0.9, 1.1]. Improvement < 0.03 AUROC, OR calibration slope outside [0.85, 1.15], falsifies it.

[KNOWLEDGE_GAP category=lab-tribal-knowledge]Is there an annotated cohort where TFE3 fusion status, pretreatment-biopsy spatial transcriptomics, and checkpoint-inhibitor response are linked at the patient level? OS is rare; this triangulation may not exist outside specialized sarcoma centers.[/KNOWLEDGE_GAP]

[KNOWLEDGE_GAP category=non-english-literature]Are there Japanese or Chinese OS spatial-transcriptomics cohorts with checkpoint outcome data that should inform external validation? Asian OS series have meaningfully different demographics and TME composition that I have weak training coverage on.[/KNOWLEDGE_GAP]
